Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study

Area of Science:

• Nephrology
• Transplantation Immunology

Background:

• Chronic allograft nephropathy is a major cause of long-term kidney graft failure.
• Tacrolimus demonstrates superior efficacy and tolerability compared to cyclosporine in managing conditions like hyperlipidemia and hypertension, which contribute to nephropathy.
• Preventing acute rejection and toxic influences is crucial for sustained kidney function.

Purpose of the Study:

• To evaluate the impact of converting from cyclosporine to tacrolimus on renal function in kidney transplant recipients.
• To assess the benefits of tacrolimus in patients experiencing deteriorating kidney function under cyclosporine therapy.

Main Methods:

• Retrospective analysis of 30 kidney transplant patients.
• Data collected for 3 years prior to and 3 years after conversion from cyclosporine to tacrolimus.
• Monitoring of renal function, including Glomerular Filtration Rate (GFR) and serum creatinine levels.

Main Results:

• Patients showed progressive decline in renal function (GFR decrease of 35 mL/min) under cyclosporine over 3 years.
• Following conversion to tacrolimus, renal function stabilized or improved, with GFR increasing by 14 mL/min and creatinine decreasing by 0.7 mg/dL.
• Tacrolimus therapy halted the decline in kidney function observed with cyclosporine.

Conclusions:

• Conversion from cyclosporine to tacrolimus is a beneficial strategy for kidney transplant patients with declining renal function.
• Tacrolimus can lead to stabilization and potential improvement in kidney transplant function, mitigating risks of chronic allograft nephropathy.